Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Management

James Bonnar

James Bonnar

Nyrada CEO

BSc (Chemistry), MRQA

James joined Nyrada, Inc. in February 2018 and brings over 20 years of global experience in the Life Sciences industry, including pre-clinical research, operations management, CMC (Chemistry, Manufacturing and Controls), Regulatory Affairs, and Quality Assurance. Before joining Nyrada, James was at Neuren for eleven years. During this period, he was the Director, CMC and Regulatory Affairs and then Director, Clinical Operations where he oversaw clinical development for drugs in the areas of traumatic brain injury and neurodevelopmental disorders. Prior to that he worked in diabetes research, GMP manufacturing, and drug formulation development.

James brings an experienced scientific focus to Nyrada, having led teams from early stage development through to end of Phase II.

Benny Evison

Dr Benny Evison

Chief Scientific Officer

B. Sc. (Med. Sci.) (Hons); PhD

Dr. Benny Evison completed his B. Sc. (Med. Sci.) (Hons) in 2001 and commenced his PhD studies in 2002 at La Trobe University (LTU), Melbourne, Australia. During his PhD at LTU (2002–2007), he gained extensive research experience in the design, development, and analysis of novel DNA-directed therapeutic agents for the treatment of cancer, particularly breast and prostate cancers and lymphomas.

Dr. Evison was appointed as a postdoctoral research fellow in the School of Molecular Sciences, LTU in 2008 where he continued his research in the development of improved anticancer drugs and mentored students at both Honours and PhD levels. He subsequently moved to world-renowned St. Jude Children’s Research Hospital, Memphis, TN, USA, to commence a second postdoctoral research fellowship (2011-2017) where he was involved in the discovery and development of novel inhibitors of DNA repair for the chemosensitisation of paediatric cancers to existing DNA damage based therapies.

In 2017, Dr. Evison returned home to Australia to begin his current post at Nyrada Inc. where he hopes to leverage his extensive scientific experience to generate novel therapeutic entities for the treatment of human diseases.